Compare OMH & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OMH | PPCB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Singapore | Australia |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 2.6M |
| IPO Year | 2022 | 2011 |
| Metric | OMH | PPCB |
|---|---|---|
| Price | $2.53 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 193.9K |
| Earning Date | 04-28-2026 | 09-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.14 | N/A |
| Revenue Next Year | $145.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.06 |
| 52 Week High | $3.75 | $6.79 |
| Indicator | OMH | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.38 |
| Support Level | N/A | $0.10 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.90 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, Digital Marketing Services, and emerging and other services. The firm operates in two segments, which are Brokerage, emerging and another related service; and Estate management services and other related services in Singapore.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.